| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000001742 |
| Receipt No. | R000002099 |
| Official scientific title of the study | Treatment protocol for acute promyelocytic leukemia -FBMTG-APL2009- |
| Date of disclosure of the study information | 2009/03/01 |
| Last modified on | 2019/03/09 (Ver. 7) |
| Basic information | ||
| Official scientific title of the study | Treatment protocol for acute promyelocytic leukemia
-FBMTG-APL2009- |
|
| Title of the study (Brief title) | FBMTG-APL2009 | |
| Region |
|
|
| Condition | ||
| Condition | acute promyelocytic leukemia | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | We plan the risk-adjusted treatment protocol for adult acute promyelocytic leukemia. The risks are determined by the MRD status post consolidation treatment. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | 3 years disease-free survival |
| Key secondary outcomes | 5 years disease free survival, CR rate, treatment-related toxicities |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 2 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | APL patients who present white blood cell count > 3,000 on admission, will receive high-dose of cytarabine plus intrathecal injection in addition to conventional chemotherapy plus ATRA therapy at the consolidation chemotherapy. | ||
| Interventions/Control_2 | APL patients who present white blood cell count < 3,000 on admission, will receive conventional chemotherapy combined with ATRA therapy. | ||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Acute promyelocytic leukemia by WHO classification
2. The first time treatment example which does not catch chemotherapy or the radiotherapy 3. The case that is equal to or less than 65 years old more than age 15 years old 4. Performance status 0-2 5. A case without the dangerously ill internal organs disorder; T.Bil equal to or less than 2.0mg/dL, Cr equal to or less than 2.0mg/dL 6. The case that an agreement by the document is provided from a patient on explanation because of final examination contents |
|||
| Key exclusion criteria | 1. The case having double cancers
2. The case with an infectious disease having difficulty with control 3. The case with a severe mental disorder 4. The pregnancy or breast-feeding woman 5. The case that the medical attendant judged to be inappropriate |
|||
| Target sample size | 50 | |||
| Research contact person | |
| Name of lead principal investigator | Tomohiko Kamimura |
| Organization | Harasanshin General Hospital |
| Division name | Department of Hematology |
| Address | 1-8 Taihaku-cho, Hakata-ku, Fukuoka 812-0033, Japan |
| TEL | |
| Public contact | |
| Name of contact person | Toshihiro Miyamoto |
| Organization | Kyushu University Hospital |
| Division name | Hematology/ Oncology |
| Address | 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan |
| TEL | 092-642-5230 |
| Homepage URL | |
| toshmiya@intmed1.med.kyushu-u.ac.jp | |
| Sponsor | |
| Institute | Fukuoka Blood & Marrow Transplant Group |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Fukuoka Blood & Marrow Transplant Group |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002099 |